Want to see SIBN full AI Analyst Report?
SIBN Stock Chart & Stats
$16.62
$0.43(2.59%)
At close: 4:00 PM EDT
$16.62
$0.43(2.59%)
Day’s Range― - ―
52-Week Range$11.48 - $21.89
Previous Close$17
Volume620.11K
Average Volume (3M)648.60K
Market Cap
$894.58M
Enterprise Value$622.72
Total Cash (Recent Filing)$145.94M
Total Debt (Recent Filing)$7.17M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 09, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding44,818,577
10 Day Avg. Volume524,959
30 Day Avg. Volume648,599
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.50Price Target Upside47.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$231.82M
Bulls Say, Bears Say
Bulls Say
Revenue, Procedure And Physician GrowthRevenue and procedure growth are broadening the commercial base, while physician adoption supports recurring implant demand. Sustained volume expansion can improve territory productivity and operating leverage, strengthening the model beyond any single product cycle.
High Gross Margins And Improving ProfitabilityThe combination of high gross margins and sharply improving adjusted EBITDA indicates meaningful operating leverage as scale increases. Continued cost optimization and better capacity utilization could support a durable path toward profitability.
Conservative Leverage And Strong LiquidityMinimal leverage and substantial equity provide financial flexibility to fund product development, commercial expansion and capacity investments without heavy reliance on debt. This strengthens resilience while the company transitions toward sustained profitability.
Bears Say
GAAP Losses And Negative Free Cash FlowDespite substantial improvement, ongoing GAAP losses and negative free cash flow mean the business has not yet become consistently self-funding. Continued investment needs could require sustained use of its cash balance before profitability is reached.
ASP And Product-Mix PressureLower revenue per case could limit sales growth and margin expansion even if procedure volumes continue rising. The company may need new products or complementary devices to offset mix-driven pricing pressure and preserve economics.
Regulatory And Commercial Launch Execution RiskFuture growth depends partly on regulatory clearance, phased commercialization and multi-quarter sales-force onboarding. Delays or slower adoption would defer product contributions, while the small international base leaves the company heavily dependent on U.S. execution.
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $11.48 and its highest was $21.89 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $894.58M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Nov 09, 2026 which is in 76 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on Aug 03, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.149 by $0.059.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.13.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,818,577 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.149. Following the earnings report the stock price went down -0.054%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (47.41% Upside)
$24.50 (47.41% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 368.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $702.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.72%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
SIBN Company Deck
SIBN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong top-line growth, expanding physician adoption, robust gross margins, and meaningful improvement in adjusted EBITDA and cash balances. Management filed a 510(k) for a third breakthrough device, expects phased commercial launch in Q4, and benefited from favorable reimbursement actions (new DRGs and proposed SI joint increases). At the same time, the company remains modestly unprofitable on a GAAP basis, is investing in capacity and R&D which will cause near-term variability in cash flow and depreciation, and is taking a conservative view on near-term guidance due to seasonality and timing of catalysts. Overall, positives (growth, margin strength, reimbursement tailwinds, product pipeline and liquidity) outweigh near-term execution and timing risks.View all SIBN earnings summariesSIBN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$24.50
▲(47.41% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
4.88% Insiders
26.21% Mutual Funds
54.87% Other Institutional Investors
1.71% Public Companies and
Individual Investors









